Log in

ASTC ASTROTECH Corp NASDAQ · United States

ASTROTECH (ASTC) news

ASTROTECH Corp is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ASTC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest ASTROTECH news

We have not published a story on ASTROTECH yet. When there is news, it will appear here.

What ASTROTECH does

Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation organized in 1984. It is commercializing its Astrotech Mass Spectrometer Technology platform through application specific, wholly owned subsidiaries. Its stated mission is to advance mass spectrometry and gas chromatography and to expand access to them through devices designed for high-volume, real-time testing. The company says it is introducing a new line of ultra-portable, on-site, rugged environmental testing instruments featuring its proprietary ATi Gas Chromatography Column and ATi Mass Spectrometer Technology. Its products named in the text are the TRACER 1000, BreathTest-1000, AGLAB 1000 and Pro-Control 1000, along with related accessories and consumables. The text names target settings including airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers and industrial locations.

Product or programWhat it isStage
ATi instrument lineUltra-portable, rugged on-site environmental testing instruments with ATi gas chromatography and mass spectrometrybeing introduced
TRACER 1000Named device in the company's product line
BreathTest-1000Named device in the company's product line
AGLAB 1000Named device in the company's product line
Pro-Control 1000Named device in the company's product line

Summarised from the company's 10-K filed Sep 25, 2026.

ASTROTECH annual financials

LineFY ended Jun 30, 2026FY ended Jun 30, 2025
Revenue$1.0 million
Research and development$6.5 million$8.1 million
Net income (loss)-$14.4 million-$13.8 million
Cash from operations-$13.5 million-$13.0 million
Cash and equivalents$8.4 million$3.1 million
Short-term investments$2.9 million$15.1 million

Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $8.4 million, plus short-term investments of $2.9 million, $11.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about ASTROTECH

What is the ticker symbol of ASTROTECH?

ASTROTECH Corp trades under the ticker ASTC on NASDAQ.

Where is ASTROTECH listed?

ASTROTECH Corp is listed on NASDAQ.

Which country or territory is ASTROTECH listed under?

Our directory records ASTROTECH Corp under United States.

Does aibio.space cover ASTROTECH?

aibio.space lists ASTROTECH Corp among 2,820 public biotech companies and publishes its news here as stories appear.

What does ASTROTECH develop?

Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation organized in 1984. It is commercializing its Astrotech Mass Spectrometer Technology platform through application specific, wholly owned subsidiaries.

What is ATi instrument line from ASTROTECH?

ATi instrument line: Ultra-portable, rugged on-site environmental testing instruments with ATi gas chromatography and mass spectrometry Stage: being introduced.

What is TRACER 1000 from ASTROTECH?

TRACER 1000: Named device in the company's product line Stage: not stated in the text.

Is ASTROTECH profitable?

ASTROTECH Corp reported a net loss of $14.4 million for the fiscal year ended Jun 30, 2026, and used $13.5 million of cash in operations, per its annual report to the SEC.

How much does ASTROTECH spend on research and development?

$6.5 million in the fiscal year ended Jun 30, 2026, per its annual report.

How much cash does ASTROTECH have?

$11.3 million in cash and short-term investments at Jun 30, 2026, per its 10-K.

Investor discussion: ASTROTECH

Members talk about ASTROTECH (ASTC). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at ASTROTECH, newest first. Each line links the filing it comes from.

  1. Financings

    Reported a financing. SEC Form 424B5. Source

  2. Financings

    Reported a financing. SEC Form 424B5. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ASTC on TradingView.

Listing details

ASTROTECH Corp is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ASTC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
ASTROTECH Corp
Ticker
ASTC
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.